|[May 19, 2014]
Research and Markets: CVT-301 (Parkinson's Disease) by Civitas Therapeutics- Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/vltc4s/cvt301)
has announced the addition of the "CVT-301
(Parkinson's Disease) - Forecast and Market Analysis to 2022"
report to their offering.
CVT-301 has been developed by Civitas Therapeutics as the company's
leading candidate for the treatment of OFF episodes in Parkinson's
disease. Using the ARCUS inhaler platform, levodopa is inhaled into the
lung where it is delivered to the blood, avoiding the gastrointestinal
tract and producing more rapid effects than orally administered
levodopa. CVT-301 will be taken as needed, similar to a rescue inhler,
which is common in the asthma market. It will not replace the patient's
current oral doses of levodopa or other medications, but will be taken
in addition to them.
Overview of Parkinson's disease, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
Detailed information on CVT-301 including product description, safety
and efficacy profiles as well as a SWOT analysis.
Sales forecast for CVT-301 for the top six countries from 2012 to 2022.
Sales information covered for the US, France, Germany, Italy, Spain
and the UK.
Reasons to buy
Understand and capitalize by identifying products that are most likely
to ensure a robust return
Stay ahead of the competition by understanding the changing
competitive landscape for Parkinson's disease
Effectively plan your M&A and partnership strategies by identifying
drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth
analysis of CVT-301 performance
Obtain sales forecast for CVT-301 from 2012-2022 in the top six
countries (the US, France, Germany, Italy, Spain and the UK).
For more information visit http://www.researchandmarkets.com/research/vltc4s/cvt301
[ Back To TMCnet.com's Homepage ]